Positive.

Validea’s guru fundamental report for JOHNSON & JOHNSON (JNJ) shows high ratings using the P/B Growth Investor model by Partha Mohanram. JNJ is a large-cap growth stock in Biotechnology & Drugs with a rating of 88%. The stock meets most criteria such as book/market ratio, return on assets, and sales variance, but fails in research and development to assets. Partha Mohanram’s academic research has shown success in growth investing strategies. Validea offers investment research services based on strategies of investment legends like Warren Buffett and Peter Lynch.

Read more at Nasdaq: Validea Detailed Fundamental Analysis – JNJ